China Shineway Pharmaceutical (2877.HK) 23Q1 - Growth Is Likely to Slow in Coming Quarters
303 Views11 May 2023 08:55
Shineway had high growth in 23Q1, but COVID-19 TCM sales would decrease in coming quarters. Since TCM formula granules will be the main performance driver, this year's strong growth will be sustained.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- China Resources Sanjiu (000999.CH) - 2023 Results Below Expectations; Short-Term Headwinds Remain25 Mar 2024
- China Shineway Pharmaceutical (2877.HK) - Performance Pressure Is About to Emerge13 Dec 2023
- China Shineway Pharmaceutical (2877.HK) - Optimistic About the Outlook Despite Short-Term Headwinds03 Oct 2023
- China Shineway Pharmaceutical (2877.HK) 23Q1 - Growth Is Likely to Slow in Coming Quarters11 May 2023
- China Shineway Pharmaceutical (2877.HK) - Strong Growth Momentum Is Expected to Continue in 202311 Apr 2023
- China Shineway Pharmaceutical (2877.HK) - Some Points Worth the Attention03 Feb 2023
- China Shineway Pharmaceutical (2877HK)-Shineway Is Undervalued, but Downside Risk Is Hard to Control27 Sep 2022
x